189 related articles for article (PubMed ID: 37672511)
21. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
Scheufele F; Friess H
Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
Tang K; Lu W; Qin W; Wu Y
Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis.
Lee YS; Lee JC; Yang SY; Kim J; Hwang JH
Sci Rep; 2019 Oct; 9(1):15662. PubMed ID: 31666626
[TBL] [Abstract][Full Text] [Related]
25. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
[TBL] [Abstract][Full Text] [Related]
26. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Jung HS; Kim HS; Kang JS; Kang YH; Sohn HJ; Byun Y; Han Y; Yun WG; Cho YJ; Lee M; Kwon W; Jang JY
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139520
[TBL] [Abstract][Full Text] [Related]
27. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
28. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
[TBL] [Abstract][Full Text] [Related]
29. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
[TBL] [Abstract][Full Text] [Related]
32. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
[TBL] [Abstract][Full Text] [Related]
33. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.
Pijnappel EN; Suurmeijer JA; Koerkamp BG; Kos M; Siveke JT; Salvia R; Ghaneh P; van Eijck CHJ; van Etten-Jamaludin FS; Abrams R; Brasiuniene B; Büchler MW; Casadei R; van Laethem JL; Berlin J; Boku N; Conroy T; Golcher H; Sinn M; Neoptolemos JP; van Tienhoven G; Besselink MG; Wilmink JW; van Laarhoven HWM
JAMA Oncol; 2022 Jun; 8(6):929-937. PubMed ID: 35446336
[TBL] [Abstract][Full Text] [Related]
34. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.
Ross SB; Popover J; Sucandy I; Christodoulou M; Pattilachan TM; Rosemurgy AS
Am Surg; 2024 Apr; ():31348241248703. PubMed ID: 38635295
[TBL] [Abstract][Full Text] [Related]
35. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
[TBL] [Abstract][Full Text] [Related]
36. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
37. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Jang JY; Han Y; Lee H; Kim SW; Kwon W; Lee KH; Oh DY; Chie EK; Lee JM; Heo JS; Park JO; Lim DH; Kim SH; Park SJ; Lee WJ; Koh YH; Park JS; Yoon DS; Lee IJ; Choi SH
Ann Surg; 2018 Aug; 268(2):215-222. PubMed ID: 29462005
[TBL] [Abstract][Full Text] [Related]
38. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
Front Oncol; 2021; 11():812102. PubMed ID: 35083158
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
